Mitchell Finer
Director/Board Member at TURMERIC ACQUISITION CORP.
Net worth: 60 555 $ as of 2023-12-30
Profile
Mitchell H.
Finer founded Cell Genesys, Inc. in 1989, where he worked as Vice President-Research from 1989 to 1999, Adverum Biotechnologies, Inc. in 2006, where he worked as Director from 2006 to 2019, Oncorus, Inc. in 2015, where he worked as Director in 2023, CODA Biotherapeutics, Inc. in 2014, where he is working as Director from 2014, and ElevateBio LLC in 2017, where he is working as Director, President-Research & Development from 2017.
Dr. Finer also founded Abgenix, Inc., where he worked as Principal.
Dr. Finer also currently works at LifeEDIT Therapeutics, Inc., as Chief Executive Officer, Semma Therapeutics, Inc., as Director from 2015, Turmeric Acquisition Corp., as Independent Director, Abata Therapeutics, Inc., as Director, Tabby Therapeutics Ltd., as Director, and Elevatebio Base Camp, Inc., as President from 2019.
Dr. Finer also formerly worked at Intracel Corp., as Chief Executive Officer from 2005 to 2007, Genteric, Inc., as President & Chief Executive Officer from 2003 to 2005, Intracel Resources LLC, as Chief Executive Officer, Intracel Holdings Corp., as Chief Executive Officer from 2005 to 2008, MPM BioImpact, Inc, as Managing Director, Candel Therapeutics, Inc., as Director, TCR2 Therapeutics, Inc., as Independent Director from 2015 to 2020, SaviCorp, as Vice President-Research & Development, ViaCyte, Inc., as Senior Vice President-Development from 2008 to 2010, Aventis Pharmaceuticals, Inc., as Vice President-Gencell Division from 1999 to 2002, Sanofi India Ltd., as Vice President-Research, and bluebird bio, Inc., as Chief Scientific Officer from 2010 to 2015.
Dr. Finer received his doctorate degree in 1986 from Harvard University and undergraduate degree in 1979 from the University of California, Berkeley.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ONCORUS, INC.
1.84% | 2023-03-30 | 480,598 ( 1.84% ) | 60 555 $ | 2023-12-30 |
Mitchell Finer active positions
Companies | Position | Start |
---|---|---|
TURMERIC ACQUISITION CORP. | Director/Board Member | - |
LifeEDIT Therapeutics, Inc.
LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Chief Executive Officer | - |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Director/Board Member | - |
Elevatebio Base Camp, Inc. | President | 2019-04-30 |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Founder | 2017-11-30 |
CODA Biotherapeutics, Inc.
CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Founder | 2013-12-31 |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Director/Board Member | 2015-03-31 |
Tabby Therapeutics Ltd.
Tabby Therapeutics Ltd. BiotechnologyHealth Technology Tabby Therapeutics Ltd. develops therapeutic drugs. The company is based in Ness Ziona, Israel. The Israeli company was founded in 2021 by Adi Barzel, Alessio D. Nahmad. | Director/Board Member | - |
Former positions of Mitchell Finer
Companies | Position | End |
---|---|---|
ONCORUS, INC. | Chief Executive Officer | 2018-06-30 |
░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Mitchell Finer
Harvard University | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 5 |
---|---|
SANOFI INDIA LIMITED | Health Technology |
BLUEBIRD BIO, INC. | Health Technology |
CANDEL THERAPEUTICS, INC. | Health Technology |
ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
ONCORUS, INC. | Health Technology |
Private companies | 19 |
---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Abgenix, Inc. developed therapeutic products. It focused on the discovery, development and manufacturing of therapeutic antibodies. The firm's antibody development platform included manufacturing fully human antibody product candidates to a variety of disease targets. The company was founded by R. Scott Greer in 1996 and was headquartered in Fremont, CA. | Health Technology |
Intracel Corp. | Health Technology |
SaviCorp
SaviCorp Movies/EntertainmentConsumer Services SaviCorp is an automotive technology company dedicated to saving the planet, one vehicle, one fleet, at a time. It creates and commercializes blow-by gas and crankcase engine emission reduction technology, which intends to develop and market on a commercial basis. The technology is a relatively simple gasoline and diesel engine emission reduction device that the company intends to sell to its customers for effective and efficient emission reduction and engine efficiency for implementation in both new and presently operating automobiles. The company’s products include Dynovalve, Dynocap, Dynoflo, Dynoplug, Fiber and water. SaviCorp was founded by Serge V. Monros on November 3, 1986 and is headquartered in Santa Ana, CA. | Consumer Services |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Genteric, Inc.
Genteric, Inc. Pharmaceuticals: MajorHealth Technology Genteric, Inc. develops revolutionary therapeutic protein delivery technology. It is a biotech company formed to commercialize several proprietary technology platforms that harness the body's own protein production and distribution system. Genteric proprietary technology captures natural protein manufacturing capability for therapeutic benefit. The company is headquartered in Redwood City, CA. | Health Technology |
Intracel Resources LLC
Intracel Resources LLC BiotechnologyHealth Technology Intracel Resources LLC specializes in the development of cardiovascular disease research solutions. Its products include spectrum encompasses lipoproteins, human lipoprotein-deficient serums and cell growth supplements. The company also supply immunotherapeutic vaccines and drugs for liposuction uses and cardiovascular applications. The company was founded in 1985 and is headquartered in Frederick, MD. | Health Technology |
Intracel Holdings Corp.
Intracel Holdings Corp. BiotechnologyHealth Technology Intracel Holdings Corp. engages in the development of vaccines and diagnostic products for cancer and infectious diseases. The company was founded in 2013 and is headquartered in Frederick, MD. | Health Technology |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
CODA Biotherapeutics, Inc.
CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Health Technology |
ElevateBio LLC
ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Health Technology |
Elevatebio Base Camp, Inc. | |
Turmeric Acquisition Corp.
Turmeric Acquisition Corp. Financial ConglomeratesFinance Turmeric Acquisition Corp. operates as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 28, 2020 and is headquartered in Cambridge, MA. | Finance |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Health Technology |
LifeEDIT Therapeutics, Inc.
LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Commercial Services |
Tabby Therapeutics Ltd.
Tabby Therapeutics Ltd. BiotechnologyHealth Technology Tabby Therapeutics Ltd. develops therapeutic drugs. The company is based in Ness Ziona, Israel. The Israeli company was founded in 2021 by Adi Barzel, Alessio D. Nahmad. | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Mitchell Finer